Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel J Bratton

Showing results (11-20 of 50) with videos related to

Pageof 5
Sort By:
The Journal of Infectious Diseases|November 24, 2012
Reply to Dodd and ProschanPatrick P J Phillips, Daniel J Bratton, Andrew J Nunn, et al.
BMJ Open|March 18, 2016
ECG risk markers for atrial fibrillation and sudden cardiac death in minimally symptomatic obstructive sleep apnoea: the MOSAIC randomised trialChristian Schlatzer, Daniel J Bratton, Sonja E Craig, et al.
Chest|January 29, 2017
Effects of CPAP and Mandibular Advancement Devices on Health-Related Quality of Life in OSA: A Systematic Review and Meta-analysisEric Kuhn, Esther I Schwarz, Daniel J Bratton, et al.
Trials|July 3, 2016
Type I error rates of multi-arm multi-stage clinical trials: strong control and impact of intermediate outcomesDaniel J Bratton, Mahesh K B Parmar, Patrick P J Phillips, et al.
Pharmaceutical Statistics|November 9, 2018
Treatment policy estimands for recurrent event data using data collected after cessation of randomised treatmentJames H Roger, Daniel J Bratton, Bhabita Mayer, et al.
Journal of Thoracic Disease|February 24, 2016
In patients with minimally symptomatic OSA can baseline characteristics and early patterns of CPAP usage predict those who are likely to be longer-term users of CPAPChristopher D Turnbull, Daniel J Bratton, Sonya E Craig, et al.
Trials|July 10, 2025
Realizing the benefits of the estimand framework when reporting and communicating clinical trial results-some recommendationsVivian Lanius, Barbara Glocker, Christian Lösch, et al.
Journal of Biopharmaceutical Statistics|September 25, 2023
Comments on "Emerging insights and commentaries - MMRM vs LOCF by Naitee Ting"David Wright, Daniel J Bratton, Thomas Drury, et al.
Trials|May 1, 2012
The value of the pragmatic-explanatory continuum indicator summary wheel in an ongoing study: the bullous pemphigoid steroids and tetracyclines studyDaniel J Bratton, Andrew J Nunn, Fenella Wojnarowska, et al.
Clinical Trials (London, England)|July 17, 2012
When inferiority meets non-inferiority: implications for interim analysesDaniel J Bratton, Hywel C Williams, Brennan C Kahan, et al.
Pageof 5

Showing results (11-20 of 50) with videos related to

Sort By:
Pageof 5
The Journal of Infectious Diseases|November 24, 2012
Reply to Dodd and ProschanPatrick P J Phillips, Daniel J Bratton, Andrew J Nunn, et al.
BMJ Open|March 18, 2016
ECG risk markers for atrial fibrillation and sudden cardiac death in minimally symptomatic obstructive sleep apnoea: the MOSAIC randomised trialChristian Schlatzer, Daniel J Bratton, Sonja E Craig, et al.
Chest|January 29, 2017
Effects of CPAP and Mandibular Advancement Devices on Health-Related Quality of Life in OSA: A Systematic Review and Meta-analysisEric Kuhn, Esther I Schwarz, Daniel J Bratton, et al.
Trials|July 3, 2016
Type I error rates of multi-arm multi-stage clinical trials: strong control and impact of intermediate outcomesDaniel J Bratton, Mahesh K B Parmar, Patrick P J Phillips, et al.
Pharmaceutical Statistics|November 9, 2018
Treatment policy estimands for recurrent event data using data collected after cessation of randomised treatmentJames H Roger, Daniel J Bratton, Bhabita Mayer, et al.
Journal of Thoracic Disease|February 24, 2016
In patients with minimally symptomatic OSA can baseline characteristics and early patterns of CPAP usage predict those who are likely to be longer-term users of CPAPChristopher D Turnbull, Daniel J Bratton, Sonya E Craig, et al.
Trials|July 10, 2025
Realizing the benefits of the estimand framework when reporting and communicating clinical trial results-some recommendationsVivian Lanius, Barbara Glocker, Christian Lösch, et al.
Journal of Biopharmaceutical Statistics|September 25, 2023
Comments on "Emerging insights and commentaries - MMRM vs LOCF by Naitee Ting"David Wright, Daniel J Bratton, Thomas Drury, et al.
Trials|May 1, 2012
The value of the pragmatic-explanatory continuum indicator summary wheel in an ongoing study: the bullous pemphigoid steroids and tetracyclines studyDaniel J Bratton, Andrew J Nunn, Fenella Wojnarowska, et al.
Clinical Trials (London, England)|July 17, 2012
When inferiority meets non-inferiority: implications for interim analysesDaniel J Bratton, Hywel C Williams, Brennan C Kahan, et al.
Pageof 5